Drug Profile
Research programme: histone deacetylase inhibitors - Merck
Alternative Names: AP CANC03; AP CANC04; IRBM-1; IRBM-D; MRLB 223Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Merck & Co
- Developer Istituto di Ricerche di Biologia Molecolare; Merck & Co
- Class Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Italy (IV)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Italy (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (IV)